ABVC BioPharma
ABVC
14 hedge funds and large institutions have $1.82M invested in ABVC BioPharma in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
0.18% more ownership
Funds ownership: 3.34% → 3.52% (+0.18%)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
24% less capital invested
Capital invested by funds: $2.39M → $1.82M (-$566K)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $43K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$107K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$54.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$39K |
| 4 |
Jane Street
New York
|
+$29.1K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$19.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$59.6K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$36.3K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$2.44K |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$456 |
ABVC Hedge Fund Activity: Q4 2025 in Review
14 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q4 2025, worth a combined $1.82M — down 24% from $2.39M a quarter earlier.
Fund positioning in ABVC was balanced in Q4 2025: 2 funds opened new positions, 2 closed out, 8 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $107K. The largest seller was Millennium Management, exiting entirely with an estimated $59.6K sold.
- 14 institutional investors held ABVC BioPharma (ABVC) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $1.82M of ABVC BioPharma stock for Q4 2025, down 24% quarter-over-quarter.
- 2 funds opened new ABVC BioPharma positions in Q4 2025 and 2 closed out, a net change of 0 holders.
- The largest ABVC BioPharma buyer in Q4 2025 was Citadel Advisors, an estimated $107K added.
- The largest ABVC BioPharma seller in Q4 2025 was Millennium Management, an estimated $59.6K sold.
Based on aggregated 13F filings for Q4 2025.